Clinical Efficacy and Safety of Gemcitabine Combined with Albumin Paclitaxel Adjuvant Chemotherapy in Patients with Pancreatic Cancer after Radical Resection
Objective To explore the clinical efficacy and safety of gemcitabine combined with albu-min paclitaxel chemotherapy in patients with pancreatic cancer after radical resection.Methods 98 pa-tients after radical surgery for pancreatic cancer were selected as the study subjects,and were divided into the observation group and the control group according to the method of randomized numerical table,each with 49 cases.The control group was treated with gemcitabine,and the observation group was treated with gemcitabine combined with albumin paclitaxel.Tumor control effects and quality of life were com-pared between the two groups,and serum tumor marker[carcinoembryonic antigen(CEA),glycan anti-gen 19-9(CA19-9),and alpha-fetoprotein(AFP)]levels,1-year and 2-year survival rate,and toxic reactions of the drugs to various organs were observed.Results After treatment,the tumor remission rate of 48.98%and the disease control rate of 85.71%in the observation group were higher than those of 28.57%and 67.35%in the control group,respectively;the quality-of-life score,1-year and 2-year sur-vival rate of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).After treatment,the serum CEA level,CA19-9 level and AFP level of the observation group were lower than those of the control group,and the difference was statistically sig-nificant(P<0.05).Comparison of the incidence rate of leukopenia,the incidence rate of abnormalities in liver and kidney functions and the incidence rate of neurotoxicity between the 2 groups showed no sta-tistically significant difference(P>0.05).Conclusion Gemcitabine combined with albumin paclitaxel for adjuvant chemotherapy after radical resection of pancreatic cancer has a definite effect,which can im-prove the quality of life,improve survival rate and have high safety.
万方数据
维普
